TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38335019

Group type: EXPERIMENTAL
Intervention: POSTCare platform
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of care process for survivorship
Number of subjects: 120
Study: 38335023

Group type: EXPERIMENTAL
Intervention: Wellinks intervention with remote health coaching, pulmonary rehabilitation, and group education; 6 coaching sessions in the first 12 weeks, followed by reduced frequency or discontinuation in the second 12 weeks.
Number of subjects: 141
Study: 38335032

Group type: EXPERIMENTAL
Intervention: brepocitinib 45 mg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: zimlovisertib 400 mg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: ropsacitinib 400 mg
Number of subjects: 194

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 194
Study: 38335169

Group type: EXPERIMENTAL
Intervention: Myofascial reorganization® (MRT) for 10 min, once a week for 6 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sham sSG (classical massage for 10 min, once a week for 6 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (CG) with no intervention
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Myofascial reorganization® (MRT)
Number of subjects: 75
Study: 38335228

Group type: EXPERIMENTAL
Intervention: Hypocaloric dietary intervention for 6 months
Number of subjects: 12
Study: 38335386

Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment (herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, Chuna therapy, KM physiotherapy)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment
Number of subjects: 86
Study: 38335467

Group type: EXPERIMENTAL
Intervention: Anthracyclines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 38335474

Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg BID
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Evobrutinib 25 mg QD
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg QD
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo (switched to evobrutinib 25 mg QD after week 24)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Open-label dimethyl fumarate (DMF) 240 mg BID
Number of subjects: 223
Study: 38335473

Group type: EXPERIMENTAL
Intervention: ONC201 (dordaviprone) monotherapy
Number of subjects: 50
Study: 38335499

Group type: EXPERIMENTAL
Intervention: Vamorolone 6 mg/kg/d
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Vamorolone 2 mg/kg/d
Number of subjects: 121

Group type: COMPARATOR
Intervention: Prednisone 0.75 mg/kg/d
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 38335531

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 92
Study: 38335850

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (electron beam and photon beam therapies)
Number of subjects: 2
Study: 38335935

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA)-driven interventions
Number of subjects: 475

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 475
Study: 38335978

Group type: EXPERIMENTAL
Intervention: Eltrombopag (150 mg, 100 mg for Asian patients) and cyclosporin A (10 mg/kg per day)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Eltrombopag and cyclosporin A
Number of subjects: 54
Study: 38336284

Group type: EXPERIMENTAL
Intervention: Acute liver failure (ALF) at admission
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Hypoxic hepatitis (HH) at admission
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: ICG clearance test
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Multivariate analysis factors
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Day 28 mortality
Number of subjects: 418
Study: 38336367

Group type: EXPERIMENTAL
Intervention: Corticosteroid-free symptomatic remission (Mayo RBS=0) (group 1)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Corticosteroid-free endoscopic remission (MES ≤1) and symptomatic remission (group 2)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Corticosteroid-free histologic remission (Geboes score <2B.0), endoscopic remission and symptomatic remission (group 3)
Number of subjects: 660
Study: 38336521

Group type: EXPERIMENTAL
Intervention: Patient-centered communication tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 38336516

Group type: EXPERIMENTAL
Intervention: Updated 2022 guidelines for preoperative transthoracic echocardiography (TTE)
Number of subjects: 15529

Group type: EXPERIMENTAL
Intervention: Updated 2022 guidelines for preoperative stress imaging
Number of subjects: 15529

Group type: EXPERIMENTAL
Intervention: Use of NT-proBNP for risk estimation
Number of subjects: 15529

Group type: EXPERIMENTAL
Intervention: Adherence to updated guidelines
Number of subjects: 15529
Study: 38336635

Group type: EXPERIMENTAL
Intervention: Experimental toothpaste (0.2% sodium hyaluronate, 67% sodium bicarbonate, 0.221% sodium fluoride)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Positive control toothpaste (67% sodium bicarbonate, 0.221% sodium fluoride)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Regular fluoride toothpaste (negative control)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Experimental toothpaste vs Positive control
Number of subjects: 110
Study: 38336649

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 1865

Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 1865

Group type: EXPERIMENTAL
Intervention: Psychological wellbeing during strict containment measures
Number of subjects: 1865
Study: 38336689

Group type: EXPERIMENTAL
Intervention: Desogestrel (DESO)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LEVO)
Number of subjects: 5
Study: 38336691

Group type: EXPERIMENTAL
Intervention: SCREEN package intervention
Number of subjects: 302

Group type: COMPARATOR
Intervention: Counselling alone
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: First telephonic follow-up
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Mean duration to reach referral centre
Number of subjects: 302
Study: 38336731

Group type: EXPERIMENTAL
Intervention: PrEPare for Work Stage 1 intervention (strength-based case management and facilitated PrEP linkage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PrEPare for Work Stage 2 intervention (1-on-1 skills training, problem-solving, and motivational interviewing adherence counseling and personalized, daily text message reminders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study: 38336779

Group type: EXPERIMENTAL
Intervention: Home-based primary care (HBPC) dementia care intervention
Number of subjects: 50
Study: 38336793

Group type: EXPERIMENTAL
Intervention: Home visit plus one-time economic incentive
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: Short-term counseling and economic incentive program
Number of subjects: 1332
Study: 38336803

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Depressed Adolescents (IPT-A) + Making Connections Intervention (MCI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy for Depressed Adolescents (IPT-A)
Number of subjects: 60
Study: 38336815

Group type: EXPERIMENTAL
Intervention: VagiBIOM suppository
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 66
Study: 38336861

Group type: EXPERIMENTAL
Intervention: PD-1 and LAG-3 blockade
Number of subjects: 1
Study: 38337191

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS)-based method for assessing prognostic indicators
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Tumor burden greater than the median
Number of subjects: 310
Study: 38337375

Group type: EXPERIMENTAL
Intervention: Miller blade laryngoscope
Number of subjects: 110

Group type: COMPARATOR
Intervention: External pressure application
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: BMI over 44.244 kg/m
Number of subjects: 110
Study: 38339248

Group type: EXPERIMENTAL
Intervention: Nivolumab plus 5-Azacitidine (3 mg/kg/dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nivolumab plus 5-Azacitidine
Number of subjects: 13
Study: 38340111

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Esketamine treatment
Number of subjects: 8
Study: 38340127

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 65

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 65
Study: 38340159

Group type: EXPERIMENTAL
Intervention: Measurement of peripheral oxygen saturation (SpO2) during the 6-Minute Walk Test
Number of subjects: 0
Study: 38340330

Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation (CLS) pacing during tilt test
Number of subjects: 17
Study: 38340349

Group type: EXPERIMENTAL
Intervention: Immediate chemotherapy (within 90 days after radium-223)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Delayed chemotherapy (more than 90 days after radium-223)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Overall (both immediate and delayed chemotherapy)
Number of subjects: 182
Study: 38340586

Group type: EXPERIMENTAL
Intervention: External attention focus walking group (EAFWG)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Internal attention focus walking group (IAFWG)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No attention focus walking group (NAFWG)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All groups (EAFWG, IAFWG, NAFWG)
Number of subjects: 102
Study: 38340677

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine 133 mg
Number of subjects: 185

Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride 50 mg
Number of subjects: 185
Study: 38340682

Group type: EXPERIMENTAL
Intervention: slDNA decrease during RT/TMZ
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: slDNA detection at pre-RT
Number of subjects: 36

Group type: COMPARATOR
Intervention: Whole cfDNA concentration
Number of subjects: 36

Group type: COMPARATOR
Intervention: slDNA peak size
Number of subjects: 36

Group type: COMPARATOR
Intervention: Corticosteroid exposition
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tumor volume
Number of subjects: 36
Study: 38340723

Group type: EXPERIMENTAL
Intervention: Higher circulating MCPyV-specific CD8 T cell frequency before anti-PD-1 treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intratumoral MCPyV-specific CD8 T cells
Number of subjects: 27
Study: 38340811

Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) 2 mg/day for 24 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) 5 mg/day for 24 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) 10 mg/day for 24 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) 2 mg/day for 48 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) 10 mg/day for 48 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate monotherapy or delayed treatment
Number of subjects: 126
Study: 38341145

Group type: EXPERIMENTAL
Intervention: Late-gadolinium-enhancement (LGE) cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 1064
Study: 38341187

Group type: EXPERIMENTAL
Intervention: 17DD vaccine
Number of subjects: 270
Study: 38341203

Group type: EXPERIMENTAL
Intervention: Fruquintinib plus SOX (S-1 and oxaliplatin)
Number of subjects: 54
Study: 38341206

Group type: EXPERIMENTAL
Intervention: Different antiretroviral regimens
Number of subjects: 229
Study: 38341207

Group type: EXPERIMENTAL
Intervention: Intermittent low-energy diet (ILED) - 2 low-energy diet days/week of 1000 kcal and 5 days/week of best NHS care healthy diet and physical activity advice
Number of subjects: 48

Group type: COMPARATOR
Intervention: Best NHS care - 7 days/week until delivery of their baby
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intermittent low-energy diet (ILED)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Best NHS care
Number of subjects: 48
Study: 38341525

Group type: EXPERIMENTAL
Intervention: Transversus thoracic muscle plane block (TTMPB) with 20 ml of 0.25% bupivacaine on each side
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pecto-intercostal fascial block (PIFB) with 20 ml of 0.25% bupivacaine on each side
Number of subjects: 80
Study: 38341528

Group type: EXPERIMENTAL
Intervention: Standard of care plus nutritional supplementation (SQ-LNS)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Standard of care plus unconditional cash transfer
Number of subjects: 480

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 480
Study: 38341590

Group type: EXPERIMENTAL
Intervention: Zero Self-Harm app intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 280
Study: 38341669

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 354
Study: 38341938

Group type: EXPERIMENTAL
Intervention: Driving pressure (ΔP) in sepsis patients
Number of subjects: 3356

Group type: EXPERIMENTAL
Intervention: Driving pressure (ΔP) in pneumonia patients
Number of subjects: 3356

Group type: COMPARATOR
Intervention: Driving pressure (ΔP) in patients ventilated for other reasons
Number of subjects: 3356

Group type: EXPERIMENTAL
Intervention: Mechanical power (MP)
Number of subjects: 3356

Group type: EXPERIMENTAL
Intervention: ICU mortality
Number of subjects: 3356

Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 3356

Group type: EXPERIMENTAL
Intervention: Duration of ventilation
Number of subjects: 3356
Study: 38342115

Group type: EXPERIMENTAL
Intervention: 9 mg oral enobosarm daily
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 18 mg oral enobosarm daily
Number of subjects: 136
Study: 38342126

Group type: EXPERIMENTAL
Intervention: Oral gepotidacin (1500 mg twice daily for 5 days)
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Oral nitrofurantoin (100 mg twice daily for 5 days)
Number of subjects: 1531

Group type: EXPERIMENTAL
Intervention: Gepotidacin
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Nitrofurantoin
Number of subjects: 1531
Study: 38342371

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (AH) using a 1,480 nm diode laser, removing approximately one-third of the zona pellucida.
Number of subjects: 698

Group type: COMPARATOR
Intervention: Control group (no assisted hatching).
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (AH)
Number of subjects: 698
Study: 38342372

Group type: EXPERIMENTAL
Intervention: Prepared seminal plasma
Number of subjects: 792

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 792
Study: 38342430

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy with adjuvant therapy
Number of subjects: 1092
Study: 38342441

Group type: COMPARATOR
Intervention: Prednisone 40 mg orally for 30 days
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: A+Z (anakinra 100 mg subcutaneously for 14 days plus zinc sulfate 220 mg orally for 90 days)
Number of subjects: 147
Study: 38342735

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) intervention consisting of 10 weekly sessions including psychoeducation about depression, life areas and values assessment, activity scheduling, and self-monitoring of satisfaction and mood.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP) as a standard of care control intervention consisting of 10 weekly sessions of reassurance, guidance, encouragement, and support.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) intervention
Number of subjects: 70
Study: 38342823

Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 37
Study: 38342986

Group type: EXPERIMENTAL
Intervention: Suaahara nutrition programme
Number of subjects: 2040
Study: 38343073

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38343144

Group type: EXPERIMENTAL
Intervention: Yoga intervention group
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) intervention group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study: 38343151

Group type: EXPERIMENTAL
Intervention: venetoclax-azacitidine
Number of subjects: 431

Group type: COMPARATOR
Intervention: placebo-azacitidine
Number of subjects: 431
Study: 38343370

Group type: EXPERIMENTAL
Intervention: Dynamic Coronary Roadmap (DCR) guidance
Number of subjects: 356

Group type: COMPARATOR
Intervention: Conventional angiography guidance (Control)
Number of subjects: 356
Study: 38343424

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 38343426

Group type: EXPERIMENTAL
Intervention: Tanezumab (subcutaneous)
Number of subjects: 23079
Study: 38343431

Group type: EXPERIMENTAL
Intervention: EMBRACE intervention
Number of subjects: 13
Study: 38343583

Group type: EXPERIMENTAL
Intervention: Higher levels of RBC, HGB, and PLT in early and middle pregnancy
Number of subjects: 1027

Group type: EXPERIMENTAL
Intervention: Higher levels of WBC in early pregnancy
Number of subjects: 1027

Group type: EXPERIMENTAL
Intervention: WBC, RBC, HGB, and PLT in early and middle pregnancy
Number of subjects: 1027

Group type: EXPERIMENTAL
Intervention: Higher levels of hematological parameters in early and middle pregnancy
Number of subjects: 1027
Study: 38343807

Group type: EXPERIMENTAL
Intervention: High-dose bolus of cholecalciferol (vitamin D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38343825

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Not on a ventilator
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Continuous monitoring data
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: IH events
Number of subjects: 737
Study: 38343833

Group type: EXPERIMENTAL
Intervention: BeWeL (45-minute virtual cultural talk)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: BeWeL plus motivational interviewing with social networks (60 minutes total)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 370
Study: 38344045

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/day)
Number of subjects: 3529
Study: 38344130

Group type: EXPERIMENTAL
Intervention: Scaling up direct-acting antiviral (DAA) treatment in prisons by 44% for 10 years (2021-2030)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scaling up HCV treatment excluding DAA pharmaceutical costs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scaling up HCV testing and treatment in prisons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Status quo scenario (baseline levels of HCV treatment)
Number of subjects: 0
Study: 38344178

Group type: EXPERIMENTAL
Intervention: 15 mg-tolvaptan administered orally for 7 consecutive days
Number of subjects: 0
Study: 38344203

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 1
Study: 38344232

Group type: EXPERIMENTAL
Intervention: Art-producing activities in a hybrid format (in-person and online) for 3 months on a weekly basis
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Art-producing activities in a hybrid format (in-person and online)
Number of subjects: 126
Study: 38344236

Group type: EXPERIMENTAL
Intervention: Behavioral and substance addictions assessment using questionnaires, including PSQI for sleep quality and Ford questionnaire for insomnia.
Number of subjects: 500
Study: 38344257

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with Bupivacaine (DB group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bupivacaine (B group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (S group)
Number of subjects: 90
Study: 38344659

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy (DR)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Proliferative diabetic retinopathy (PDR)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Severity of diabetic retinopathy (DR)
Number of subjects: 272
Study: 38344760

Group type: EXPERIMENTAL
Intervention: Engagement with Targeted Inserts
Number of subjects: 18080

Group type: EXPERIMENTAL
Intervention: Email (opened)
Number of subjects: 18080

Group type: EXPERIMENTAL
Intervention: Email (clicked links)
Number of subjects: 18080

Group type: EXPERIMENTAL
Intervention: Website (logging in)
Number of subjects: 18080

Group type: EXPERIMENTAL
Intervention: Website (tracking)
Number of subjects: 18080

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Number of subjects: 18080
Study: 38344820

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 5047

Group type: COMPARATOR
Intervention: Insulin glargine, glimepiride, sitagliptin
Number of subjects: 5047
Study: 38344871

Group type: EXPERIMENTAL
Intervention: CoDE-ACS at presentation
Number of subjects: 4105

Group type: EXPERIMENTAL
Intervention: CoDE-ACS at 1 hour
Number of subjects: 4105

Group type: EXPERIMENTAL
Intervention: CoDE-ACS at 2 hours
Number of subjects: 4105

Group type: COMPARATOR
Intervention: ESC 0/1-hour pathway
Number of subjects: 4105

Group type: COMPARATOR
Intervention: ESC 0/2-hour pathway
Number of subjects: 4105

Group type: COMPARATOR
Intervention: High-STEACS pathway
Number of subjects: 4105
Study: 38344891

Group type: EXPERIMENTAL
Intervention: Buloxibutid (C21) intra-arterial infusion at doses of 3, 10, 30, 100, and 200 μg/min
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP) infusion at doses of 0.8-3.2 μg/min
Number of subjects: 5
Study: 38345056

Group type: EXPERIMENTAL
Intervention: Systemic inflammatory markers (Ro52, Scl-70, CN-1A, PM-Scl100, Sm, U2SnRNP A', La, DNA, Ro60, PL-7)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Systemic inflammatory markers
Number of subjects: 481
Study: 38345071

Group type: COMPARATOR
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 3973
Study: 38345269

Group type: EXPERIMENTAL
Intervention: Carfilzomib, daratumumab, and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pomalidomide plus bortezomib and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daratumumab plus pomalidomide and dexamethasone
Number of subjects: 0